CD47 and hematologic disorder: However, as CD47 monoclonal antibodies such as magrolimab have demonstrated an absence of efficacy in pivotal clinical trials for hematologic malignancies and have exhibited significant hematologic toxicity, clinical research targeting CD47 faces challenges [44, 45].